Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology

May 10, 2017 —  Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm management (CRM) devices with technology that automatically recognizes when a patient enters a magnetic resonance imaging (MRI) environment.

Biotronik's MRI AutoDetect technology ensures patients with CRM devices can safely undergo MRI scans while minimizing programming burdens for hospitals. Once activated by a physician, MRI AutoDetect can automatically recognize when the patient enters an MRI environment and convert the device to MRI mode. When the scan is complete, MRI AutoDetect automatically returns the device to its permanent program. Physicians can program MRI AutoDetect to be active for up to 14 days, allowing patients the flexibility to undergo, reschedule or repeat MRI scans as needed during the set timeframe.

MRI AutoDetect is currently available on Biotronik's newest line of CRM devices, including the Ilivia series for tachycardia.

The company will highlight its CRM solutions at the Heart Rhythm Society's (HRS) 38th Annual Scientific Sessions, May 10-13 in Chicago.

For more information: www.biotronik.com